Long-term outcomes after initiation of second line therapy for GVHD, stratified by choice of treatment and biomarker risk. (A) Cumulative incidence of NRM and (B) Kaplan-Meier estimates of OS for patients according to the use of ruxolitinib-based therapies (yes or no) for second line therapy of GVHD. (C) NRM and (D) OS for patients according to high or low MAP. (E) NRM and (F) OS for patients after initiation of second-line treatment for GVHD, stratified by the choice of second line therapy and MAP. The log-rank test was used for the comparison of OS and the Gray test was used for the comparison of the cumulative incidence of NRM. OS, overall survival; Rux, ruxolitinib.